Genotyping Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Genotyping Market 

5.1. COVID-19 Landscape: Genotyping Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Genotyping Market, By Product

8.1. Genotyping Market, by Product, 2024-2033

8.1.1. Instruments

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Sequencers & Amplifiers

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Analyzers

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Reagents & Kits

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Software and Services

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Genotyping Services

8.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Genotyping Market, By Application

9.1. Genotyping Market, by Application, 2024-2033

9.1.1. Pharmacogenomics

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Diagnostics and Personalized Medicine

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Agricultural Biotechnology

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Animal Genetics

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Genotyping Market, By March 

10.1. Genotyping Market, by March, 2024-2033

10.1.1. PCR

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Capillary Electrophoresis

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Microarrays

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Sequencing

10.1.4.1. Market Revenue and Forecast (2021-2033)

10.1.5. Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-TOF) Mass Spectroscopy

10.1.5.1. Market Revenue and Forecast (2021-2033)

10.1.6. Others

10.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Genotyping Market, By End User

11.1. Genotyping Market, by End User, 2024-2033

11.1.1. Pharmaceutical And Biopharmaceutical Companies

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Diagnostics And Research Laboratories

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Academic Institutes

11.1.3.1. Market Revenue and Forecast (2021-2033)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Genotyping Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product (2021-2033)

12.1.2. Market Revenue and Forecast, by Application (2021-2033)

12.1.3. Market Revenue and Forecast, by March (2021-2033)

12.1.4. Market Revenue and Forecast, by End User (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product (2021-2033)

12.1.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.1.5.3. Market Revenue and Forecast, by March (2021-2033)

12.1.5.4. Market Revenue and Forecast, by End User (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product (2021-2033)

12.1.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.1.6.3. Market Revenue and Forecast, by March (2021-2033)

12.1.6.4. Market Revenue and Forecast, by End User (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product (2021-2033)

12.2.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.3. Market Revenue and Forecast, by March (2021-2033)

12.2.4. Market Revenue and Forecast, by End User (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product (2021-2033)

12.2.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.5.3. Market Revenue and Forecast, by March (2021-2033)

12.2.5.4. Market Revenue and Forecast, by End User (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product (2021-2033)

12.2.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.6.3. Market Revenue and Forecast, by March (2021-2033)

12.2.6.4. Market Revenue and Forecast, by End User (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product (2021-2033)

12.2.7.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.7.3. Market Revenue and Forecast, by March (2021-2033)

12.2.7.4. Market Revenue and Forecast, by End User (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product (2021-2033)

12.2.8.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.8.3. Market Revenue and Forecast, by March (2021-2033)

12.2.8.4. Market Revenue and Forecast, by End User (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product (2021-2033)

12.3.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.3. Market Revenue and Forecast, by March (2021-2033)

12.3.4. Market Revenue and Forecast, by End User (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product (2021-2033)

12.3.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.5.3. Market Revenue and Forecast, by March (2021-2033)

12.3.5.4. Market Revenue and Forecast, by End User (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product (2021-2033)

12.3.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.6.3. Market Revenue and Forecast, by March (2021-2033)

12.3.6.4. Market Revenue and Forecast, by End User (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product (2021-2033)

12.3.7.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.7.3. Market Revenue and Forecast, by March (2021-2033)

12.3.7.4. Market Revenue and Forecast, by End User (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product (2021-2033)

12.3.8.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.8.3. Market Revenue and Forecast, by March (2021-2033)

12.3.8.4. Market Revenue and Forecast, by End User (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product (2021-2033)

12.4.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.3. Market Revenue and Forecast, by March (2021-2033)

12.4.4. Market Revenue and Forecast, by End User (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product (2021-2033)

12.4.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.5.3. Market Revenue and Forecast, by March (2021-2033)

12.4.5.4. Market Revenue and Forecast, by End User (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product (2021-2033)

12.4.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.6.3. Market Revenue and Forecast, by March (2021-2033)

12.4.6.4. Market Revenue and Forecast, by End User (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product (2021-2033)

12.4.7.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.7.3. Market Revenue and Forecast, by March (2021-2033)

12.4.7.4. Market Revenue and Forecast, by End User (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product (2021-2033)

12.4.8.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.8.3. Market Revenue and Forecast, by March (2021-2033)

12.4.8.4. Market Revenue and Forecast, by End User (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product (2021-2033)

12.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.5.3. Market Revenue and Forecast, by March (2021-2033)

12.5.4. Market Revenue and Forecast, by End User (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product (2021-2033)

12.5.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.5.5.3. Market Revenue and Forecast, by March (2021-2033)

12.5.5.4. Market Revenue and Forecast, by End User (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product (2021-2033)

12.5.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.5.6.3. Market Revenue and Forecast, by March (2021-2033)

12.5.6.4. Market Revenue and Forecast, by End User (2021-2033)

Chapter 13. Company Profiles

13.1. Illumina Inc

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Thermo Fisher Scientific Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Qiagen Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. F. Hoffmann-La Roche Ltd.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Fluidigm Corporation

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Danaher Corporation

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Agilent Technologies

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Eurofins Scientific Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. GE Healthcare Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Bio-Rad Laboratories Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms